Tanja Obradovic: At ASCO 2024 at the ICON plc booth we share thoughts on latest in cancer treatment innovation
Tanja Obradovic
”This year we are certain to hear many updates at ASCO 2024 around early phase possibly new treatments as well as potentially practice changing outcomes of numerous Phase 3 studies across tumor types. Looking forward to meet many of my colleagues from the clinical oncology development as a member of the ICON plc team. Positive of very productive discussions at sessions and at the ICON plc booth 30119 as we share thoughts on latest in cancer treatment innovation and how to meet patient needs in a best possible way.”
Quoting ICON plc’s post:
”Over the past five years, ICON has participated in 800+ oncology and haematologic malignancy clinical studies globally.
Meet ICON experts at ASCO24, booth #30119 to learn how our flexible and fully customisable solutions support all elements of drug development from candidate selection through to market authorisation and patient access.”
Source: Tanja Obradovic/LinkedIn and ICON plc/LinkedIn
Tanja Obradovic is the Vice President of Oncology Scientific Affairs at ICON PLCh. She has over 20 years of clinical research experience and has led major pharmaceutical companies for 13 years. Her research focuses on small molecules, antibodies, cell and gene therapy, and major immunotherapy of PD1 inhibitors.